Tandem Diabetes Care (NSDQ:TNDM) today posted third quarter earnings and lifted its sales guidance for the year, beating Wall Street expectations for sales but falling behind on losses-per-share.
The San Diego-based company posted losses of $34.2 million, or 62¢ per share, on sales of $46.3 million for the three months ended September 30, seeing losses grow 113.6% while sales grew 71.3% compared with the same period during the previous year.
Read the whole story on our sister site, Drug Delivery Business News